Dr Paul Finn, CSO of Oxford Drug Design

Dr Paul Finn, CSO of Oxford Drug Design Oxford Drug Design, a pre-clinical stage therapeutics spinout from Oxford University, is discovering innovative anti-cancer therapeutics supported by pioneering computational methods. At the cutting edge of machine learning and AI applied to pre-clinical drug discovery, Oxford Drug Design is also expanding to provide its proprietary computational capabilities to third parties to advance their internal programmes.

Download